Targeting DNA
Targeting DNA
Jef Akst | Jun 1, 2012
After 20 years of high-profile failure, gene therapy is finally well on its way to clinical approval.
Underground Supermodels
Underground Supermodels
Thomas J. Park and Rochelle Buffenstein | Jun 1, 2012
What can a twentysomething naked mole-rat tell us about fighting pain, cancer, and aging?
Best Places to Work Industry, 2012
The Scientist Staff | Jun 1, 2012
Much has changed in the 10 years since our first survey of industry researchers. Large companies are now looking to small, nimble ones for services as well as innovation.
Data Diving
Kerry Grens | May 1, 2012
What lies untapped beneath the surface of published clinical trial analyses could rock the world of independent review.
Freezing Time
Vern L. Schramm | May 1, 2012
Targeting the briefest moment in chemistry may lead to an exceptionally strong new class of drugs.
Telomeres in Disease
Rodrigo Calado and Neal Young | May 1, 2012
Telomeres have been linked to numerous diseases over the years, but how exactly short telomeres cause diseases and how medicine can prevent telomere erosion are still up for debate.
Best Places to Work Postdocs, 2012
Sabrina Richards | Apr 2, 2012
Much has changed in the last 10 years for postdocs, who are staying in their positions longer than ever before—and coming out with more to show for it.
Deliberating Over Danger
The Scientist Staff | Apr 1, 2012
The creation of H5N1 bird flu strains that are transmissible between mammals has thrown the scientific community into a heated debate about whether such research should be allowed and how it should be regulated.
Are Cancer Stem Cells Ready for Prime Time?
Are Cancer Stem Cells Ready for Prime Time?
Suling Liu, Hasan Korkaya, and Max S. Wicha | Apr 1, 2012
A flood of new discoveries has refined our definition of cancer stem cells. Now it’s up to human clinical trials to test if they can make a difference in patients.
What it Takes to Develop Better Drugs for Kids
J. Steven Leeder | Mar 1, 2012
Over the past 15 years, new laws and regulations in the United States and the European Union have expanded to require the inclusion of pediatric patients in clinical drug trials.